<code id='AE204395EB'></code><style id='AE204395EB'></style>
    • <acronym id='AE204395EB'></acronym>
      <center id='AE204395EB'><center id='AE204395EB'><tfoot id='AE204395EB'></tfoot></center><abbr id='AE204395EB'><dir id='AE204395EB'><tfoot id='AE204395EB'></tfoot><noframes id='AE204395EB'>

    • <optgroup id='AE204395EB'><strike id='AE204395EB'><sup id='AE204395EB'></sup></strike><code id='AE204395EB'></code></optgroup>
        1. <b id='AE204395EB'><label id='AE204395EB'><select id='AE204395EB'><dt id='AE204395EB'><span id='AE204395EB'></span></dt></select></label></b><u id='AE204395EB'></u>
          <i id='AE204395EB'><strike id='AE204395EB'><tt id='AE204395EB'><pre id='AE204395EB'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:7
          Sen. Bernie Sanders, I-Vt., chairman of the Senate Health, Education, Labor, and Pensions Committee listens during a hearing on Capitol Hill in Washington – politics and policy coverage from STAT
          Senate health committee Chair Bernie Sanders (I-Vt.) wants to reward new medicines with prize money. Jose Luis Magana/AP

          WASHINGTON — Sen. Bernie Sanders (I-Vt.) will finally get a study of his proposal to do away with drug patents and other intellectual property protections in favor of rewarding inventions with prize money. Sanders has been pushing the prize approach since he was a House representative, many years ago.

          The measure directing the National Academies of Sciences, Engineering and Medicine to study the idea was added to the Pandemic All-Hazards and Preparedness Act a day before Sander’s health committee passed the bill. Three Republicans voted against the overall bill, which renews several federal biodefense and pandemic-preparedness programs.

          advertisement

          Though Democrats last year passed historic legislation to let Medicare negotiate drug prices and cap seniors’ annual out-of-pocket drug costs, Sanders is demanding more drug price controls. He is delaying President Biden’s pick for running the National Institutes of Health until the president releases a plan to control drug prices.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more
          Walmart eyes Medicare Advantage provider ChenMed
          Walmart eyes Medicare Advantage provider ChenMed

          Walmartseemspoisedtoincreaseitshealthcarefootprintbybuyingvalue-basedseniorcarecompanyChenMed.JoeRae

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Food makers tried to stack nutrition panel with preferred experts

          There’sapanelof20nutritionexpertsthathasoutsizedinfluenceontheAmericandiet—andthefoodindustryhaswork